Advance amount related to milestone payment.

No definition available.

Name:	LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Agreement term description.

+ References

No definition available.

+ Details

Name:	LIXT_AgreementTermDescription
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount related to milestone payment.

+ References

No definition available.

+ Details

Name:	LIXT_AmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Company is obligated to pay annual license maintenance fee..

+ References

No definition available.

+ Details

Name:	LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Consulting and advisory quarterly cash fee.

+ References

No definition available.

+ Details

Name:	LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract price

+ References

No definition available.

+ Details

Name:	LIXT_ContractPrice
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum amount received under agreement.

+ References

No definition available.

+ Details

Name:	LIXT_MaximumAmountReceivedUnderAgreement
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	LIXT_MilestonePayments
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Company is obligated to pay non refundable license issue fee..

+ References

No definition available.

+ Details

Name:	LIXT_NonRefundableLicenseIssueFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.

+ References

No definition available.

+ Details

Name:	LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of proceeds agree to pay under agreement

+ References

No definition available.

+ Details

Name:	LIXT_PercentageOfProceedsAgreeToPayUnderAgreements
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reimbursement expense.

+ References

No definition available.

+ Details

Name:	LIXT_ReimbursementExpense
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense for employee benefit and equity-based compensation.

+ References

No definition available.

+ Details

Name:	us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of the nature and terms of commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.

+ References

No definition available.

+ Details

Name:	us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MaterialTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_INSERMMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=LIXT_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=LIXT_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=LIXT_FirstFourYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MasterServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_FoundationForAngelmanSyndromeTherapyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details Narrative) - USD ($)										2 Months Ended	3 Months Ended		6 Months Ended
	Jun. 10, 2022	Apr. 09, 2021	Feb. 05, 2021	Aug. 12, 2020	Sep. 12, 2018	Aug. 20, 2018	Mar. 22, 2018	Sep. 14, 2015	Dec. 24, 2013	Aug. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Contractual commitment											$ 8,147,000		$ 8,147,000
Research and development costs											164,810	$ 262,415	623,261	$ 705,941
City of Hope [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected											296,000		296,000
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment													67,582
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee									$ 4,000		4,000	4,000	8,000	8,000
Clinical Trial Research Agreement [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment													6,073	10,309
Research and development costs													9,405	17,693
Research and development costs													$ 114,082
Aggregate commitments expected, description													The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $594,000 as of June 30, 2022, which is expected to be incurred through December 31, 2025
Aggregate commitments expected											594,000		$ 594,000
Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment													0	24,171
Research and development costs													$ 155,053
Aggregate commitments expected, description													The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $4,166,000 as of June 30, 2022, which is expected to be incurred through December 31, 2025
Aggregate commitments expected											4,166,000		$ 4,166,000
Collaboration Agreement [Member] \| BioPharmaWorks LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee								$ 10,000
Reimbursed expense											30,000	30,000	60,000	60,000
Development Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs											0		292,293
Other Clinical Agreements [Member]
Loss Contingencies [Line Items]
Research and development costs													1,138,000
Aggregate commitments expected											20,000		20,000
Clinical Research Support Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected											800,000		800,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Research and development costs											0	285,020	0	525,528
Aggregate commitments expected											2,433,000		2,433,000
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs													99,723
Aggregate commitments expected											862,000		862,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment											11,235	10,773	15,735	14,313
Research and development costs			$ 335,000
Aggregate commitments expected											40,361		40,361
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs					$ 954,000						4,558	7,540	7,839	8,481
Material Transfer Agreement [Member] \| INSERM [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected											0		0		$ 0
Material Transfer Agreement [Member] \| INSERM [Member] \| Development Milestones [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments							$ 1,750,000
Material Transfer Agreement [Member] \| INSERM [Member] \| Commercial Milestones [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments							$ 6,500,000
Exclusive License Agreement [Member] \| First Four Years [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties													50,000
Exclusive License Agreement [Member] \| Five Years And Thereafter [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties													100,000
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Non-refundable license issue fee						$ 25,000
Annual license maintenance fee						25,000
Payments on non-refundable milestone						$ 1,897,000
Amount charges to operations											6,233	6,233	12,398	12,397
Employment Agreement [Member] \| Executive Officers [Member]
Loss Contingencies [Line Items]
Salary and Wage, Excluding Cost of Good and Service Sold										$ 640,000
Agreement term description										one-year period
Employment Agreement [Member] \| Dr.James [Member]
Loss Contingencies [Line Items]
Annual compensation		$ 775,000
Master Service Agreement [Member] \| Foundation for Angelman Syndrome Therapy [Member]
Loss Contingencies [Line Items]
Percentage of proceeds agree to pay under agreement				5.00%
Maximum amount received under agreement				$ 250,000
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment											48,886		103,116
Research and development costs													$ 158,364
Aggregate commitments expected, description													The Company’s aggregate commitment pursuant to this collaboration agreement, less amounts previously paid to date, totaled approximately $361,000 as of June 30, 2022, which is expected to be incurred through June 30, 2025.
Aggregate commitments expected											361,000		$ 361,000
MRI Global [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment											19,597	$ 15,423	20,353	$ 17,432
Contract price	$ 273,980
Clinical Trial Monitoring Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected											$ 64,000		$ 64,000